Tech Company Financing Transactions
Pathalys Pharma Funding Round
Pathalys Pharma closed a $105 million Series B funding round on 8/20/2024. Backers included TCGX, Catalys Pacific and DaVita Venture Group.
Transaction Overview
Company Name
Announced On
8/20/2024
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4242 Six Forks Rd 820
Raleigh, NC 27609
USA
Raleigh, NC 27609
USA
Phone
Undisclosed
Website
Email Address
Overview
At Pathalys Pharma, Inc. we are committed to improving the lives of patients through the development of enhanced therapeutics that improve the management of chronic kidney disease (CKD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neal Fowler
Chief Medical Officer
Theodore Danoff
Chief Operating Officer
Patrick Treanor
Co-Founder
Ashwin Ram
Co-Founder
Jay Shepard
VP - Finance
Greg Klatt
Browse more venture capital transactions:
Prev: 8/20/2024: Clarium venture capital transaction
Next: 8/20/2024: Gradient Labs venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs